Investment ProfessionalsBB Biotech AG
ISIN-No.: CH0038389992
YTD: -12.80%
Active share: 80.28
Anzahl Positionen: 31
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 20.12.2024)
Share price: CHF 35.70 (19.12.2024)
NAV: CHF 41.55 (19.12.2024)
Rolling performance (20.12.2024)
| Share Price | NAV | Benchmark | |
| 19.12.2023 - 19.12.2024 | -9.41% | 1.40% | 6.30% |
| 19.12.2022 - 19.12.2023 | -22.75% | -6.41% | -4.95% |
| 17.12.2021 - 19.12.2022 | -22.02% | -12.11% | -11.99% |
| 17.12.2020 - 17.12.2021 | 9.80% | -11.41% | 4.01% |
Annualized performance (20.12.2024)
| Share Price | NAV | Benchmark | |
| 1 year | -9.41% | 1.40% | 6.30% |
| 3 years | -18.28% | -5.87% | -3.84% |
| 5 years | -7.37% | -1.58% | 1.51% |
| 10 years | 2.04% | 1.15% | 2.32% |
| Since Inception p.a. | 9.59% | 10.12% | 8.79% |
Cumulative performance (20.12.2024)
| Share Price | NAV | Benchmark | |
| 1M | -0.83% | -1.66% | -0.66% |
| YTD | -12.80% | 2.48% | 6.06% |
| 1 year | -9.41% | 1.40% | 6.30% |
| 3 years | -45.43% | -16.59% | -11.08% |
| 5 years | -31.82% | -7.67% | 7.78% |
| 10 years | 22.40% | 12.08% | 25.84% |
| Since Inception | 1'626.42% | 1'908.19% | 1'275.40% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2023 | -18.15% | -7.39% | -4.79% |
| 2022 | -24.29% | -11.00% | -9.09% |
| 2021 | 8.34% | -11.45% | 2.98% |
| 2020 | 19.35% | 24.26% | 15.80% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (30.11.2024, base currency CHF)
| Beta | 1.34 |
| Volatility | 32.37 |
| Tracking error | 15.05 |
| Active share | 80.28 |
| Correlation | 0.92 |
| Sharpe ratio | 0.01 |
| Information ratio | 0.14 |
| Jensen's alpha | 2.83 |
| No. of positions | 31 |
Portfolio as at 30.09.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
In November, the spotlight was on the election of Donald Trump as US president. A key point of interest was Trump’s proposed appointment of Robert F. Kennedy Jr. as the Head of the Health and Human Services Department (HHS), though this nomination awaits Senate approval. Additionally, the announcement of Dr. Martin Makary as the new FDA Commissioner got attention, given the FDA's important role in drug approvals based on safety and efficacy data. As we navigate the evolving US political landscape, we are particularly focused on developments that impact the biotech industry.
Please find below selected highlights from a few of BB Biotech´s portfolio companies in November:
Argenx (+5.2%, in USD) announced on November 20 the decision to continue the development of their lead asset efgartigimod in all three subsets of myositis following the interim read-out of the Phase II. The Phase II has already been enrolling patients “at risk” to speed up the development in these high need indications.
Sage Therapeutics (-10.0%, in USD) announced on November 20 topline results from the Phase II DIMENSION study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary and secondary endpoints. Based on these results, the company does not plan to further develop dalzanemdor.
Biohaven (-7.5%, in USD) announced on November 25 an update regarding their clinical trial with taldefgrobep alfa in Spinal Muscular Atrophy (SMA). Despite some encouraging trends observed in the taldefgrobep alfa arm across multiple motor function endpoints the magnitude of effect did not turn out to be statistically different compared to placebo.
Scholar Rock (40.3%, in USD) share did appreciate on the back of Biohaven's taldefgrobep alpha’s failure in spinal muscular atrophy (SMA) as the company has now a competitor less. Scholar Rock’s lead asset apitegromab is set to become the first-in class myostatin agent in SMA.
Documents
Show moreShow less
